Jennison Associates
Overview
Jennison Associates is a global investment management firm that specializes in a select range of active equity and fixed income investment strategies.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Clover Health | Jan 2021 | IPO | Co-investor |
| Reunion Neuroscience Inc. | Mar 2021 | Follow-on Offering | Co-investor |
Key People
Dmitri Rabin
Head of Structured Finance and Lead Core Portfolio Manager, Managing Director and Portfolio Manager
Edward Duggan
Managing Director, Global Equity Portfolio Manager
Jonathan Shapiro
Managing Director
Kerry Shanley
Managing Director
Nick Rubinstein
Managing Director
Peter H. Reinemann, CFA
Managing Director
Tom Davis
Managing Director, Portfolio Manager - Global Equities
Warren Koontz
Managing Director, Portfolio Manager, Head of Large Cap Value
Wei Zhang
Managing Director
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Jennison Associates based?
Jennison Associates is headquartered in New York City, New York, United States.
When was Jennison Associates founded?
Jennison Associates was founded in 1969.
How many portfolio companies does Jennison Associates have?
Jennison Associates has 2 portfolio companies in Caplight's dataset.
What are some companies in Jennison Associates's portfolio?
Portfolio companies visible on Caplight include Clover Health, Reunion Neuroscience Inc..
What was Jennison Associates's most recent investment shown here?
Jennison Associates's most recent investment in this portfolio sample was in Reunion Neuroscience Inc. in 2021.
What sectors does Jennison Associates focus on?
Jennison Associates focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Enterprise Software.
What company stages does Jennison Associates focus on?
Stage focus information for Jennison Associates is not publicly available.
What is Jennison Associates's AUM?
Jennison Associates's assets under management are estimated between $220.0B and $220.0B.